GlaxoSmithKline plc (NYSE:GSK) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP raised its stake in GlaxoSmithKline plc (NYSE:GSK) by 440.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,486,766 shares of the pharmaceutical company’s stock after acquiring an additional 2,026,700 shares during the quarter. Two Sigma Advisers LP owned approximately 0.10% of GlaxoSmithKline worth $101,435,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Marshall Wace North America L.P. acquired a new stake in shares of GlaxoSmithKline during the 1st quarter worth approximately $62,000. New York State Common Retirement Fund raised its position in shares of GlaxoSmithKline by 248.6% during the 1st quarter. New York State Common Retirement Fund now owns 361,389 shares of the pharmaceutical company’s stock worth $13,693,000 after purchasing an additional 257,727 shares during the period. WASHINGTON TRUST Co bought a new position in GlaxoSmithKline in the 1st quarter worth approximately $53,000. Bartlett & Co. LLC bought a new position in GlaxoSmithKline in the 1st quarter worth approximately $191,000. Finally, Oppenheimer & Co. Inc. grew its holdings in GlaxoSmithKline by 12.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 82,832 shares of the pharmaceutical company’s stock worth $3,138,000 after buying an additional 9,209 shares in the last quarter. 12.12% of the stock is owned by institutional investors.

GSK stock traded up $0.15 during trading on Wednesday, reaching $39.42. 2,088,694 shares of the stock were exchanged, compared to its average volume of 3,775,612. GlaxoSmithKline plc has a twelve month low of $31.43 and a twelve month high of $48.25. The company has a market capitalization of $98.89 billion, a P/E ratio of 11.70, a price-to-earnings-growth ratio of 2.85 and a beta of 0.65. The stock has a 50 day simple moving average of $40.11 and a 200-day simple moving average of $40.27. The company has a current ratio of 0.96, a quick ratio of 0.69 and a debt-to-equity ratio of 1.28.

GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, July 29th. The pharmaceutical company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.01). GlaxoSmithKline had a return on equity of 31.21% and a net margin of 19.03%. The firm had revenue of $9.46 billion for the quarter, compared to analyst estimates of $9.60 billion. Equities analysts predict that GlaxoSmithKline plc will post 3.03 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.4914 per share. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.47. The ex-dividend date of this dividend is Thursday, August 13th. This represents a $1.97 dividend on an annualized basis and a yield of 4.99%. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 61.20%.

A number of brokerages recently issued reports on GSK. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday, August 12th. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating and set a $41.00 price objective for the company. in a research report on Tuesday. AlphaValue upgraded GlaxoSmithKline to a “buy” rating in a research report on Tuesday, September 1st. Morgan Stanley reiterated an “underweight” rating on shares of GlaxoSmithKline in a research report on Tuesday, September 1st. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, September 8th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $41.00.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline purchased 361,111 shares of the business’s stock in a transaction on Tuesday, July 21st. The stock was purchased at an average price of $18.00 per share, for a total transaction of $6,499,998.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is owned by company insiders.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: Price to Earnings Ratio (PE) Basics

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.